incagn02385
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 18, 2018 (NCT03538028)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Head and Neck Neoplasms · Phase 2
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 1
- Ovarian Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594559 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06290622 | Phase 1 | Aug 30, 2024 | University of Alabama, Birmingham |
| NCT06056895 | Phase 2 | Nov 8, 2023 | Incyte, University of Washington |
| NCT05287113 | Phase 2 | Nov 14, 2022 | Incyte |
| NCT04370704 | Phase 1/Phase 2 (Phase 2) | Jul 26, 2020 | Incyte |
| NCT03538028 | Phase 1 | Jun 18, 2018 | Incyte |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 4 | 3 | 2 | 2018 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1